{"editorial":{"content_id":"0eb923d5-d0c9-4f60-9a98-a7894aca1050","slug":"article-20261029-3295a0","content_type":"news","title":"液体活检癌症筛查进入巴西，可筛查50多种肿瘤","summary":"由Einstein与Grupo Fleury合资的Genesis Genomics在巴西推出Galleri液体活检检测，可筛查50多种肿瘤，作为癌症预防性筛查的补充工具。","body":"由Einstein与Grupo Fleury合资成立的基因组医学企业Genesis Genomics在巴西推出一项名为Galleri的液体活检检测，可对50多种肿瘤进行筛查，适用于50岁以上无症状人群、有一级亲属癌症家族史者以及有吸烟等风险因素的人群。该检测通过普通血液样本进行，属于微创方法，仅作为癌症预防性筛查的补充，不替代乳腺X线摄影和结肠镜检查等官方筛查方案。\n\n液体活检通过血液样本检测循环肿瘤DNA片段、细胞或其他肿瘤释放的标志物，用于提示体内是否存在肿瘤，而非确诊手段。若结果呈阳性，需进一步检查确认；若诊断性检查未在所指部位发现异常，可在3至6个月内免费复检一次。\n\n该技术结合机器学习与算法，可识别肿瘤DNA片段的来源部位，例如肺、胰腺或肠道。Einstein精准医学项目医疗经理、肿瘤科医生Fernando Moura表示，这是“一场革命的入口”，未来几代人将能够通过血液进行癌症筛查。\n\n在临床实践中，液体活检已用于肿瘤基因分型以选择治疗方案，以及检测治疗期间或治疗后体内残留的微量癌细胞（微小残留病灶）。巴西病理学会（SBP）病理委员会代表Isabella Werneck指出，其中一个用途是在肿瘤切除术后评估体内是否仍有病灶及是否存在微转移，从而更好地调整治疗。\n\nGalleri检测的支持数据来自PATHFINDER 2研究，该研究于2021年12月至2024年7月在美国和加拿大开展，超过3.5万人参与。在癌症信号阳性结果中，71%最终诊断为I至III期早期肿瘤，预测可能来源的准确率为91.3%，特异性为99.6%，假阳性率为0.4%至0.8%。Einstein的患者及家属已开始寻求该检测，首批结果将在未来几周内出现。\n\nMoura强调，该检测不替代官方筛查方案，而是作为补充。Werneck表示，肿瘤分层将不断完善，走向更个性化的治疗，这一趋势将持续。Moura预计，未来多组学视角将扩展，除DNA外还可分析RNA、蛋白质等；尿液等样本也有望用于筛查，尤其是肾、输尿管、膀胱乃至前列腺肿瘤，通过检测微小RNA进行评估。他还认为，未来10至15年将出现非常先进的机会、策略和技术，唾液、脑脊液、汗液等其他生物体液也可能用于微创液体活检。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["科技","行业趋势","br-health"],"content_level":"编辑整理","event_type":"行业趋势","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-10-29T11:04:06.361Z","display_date":"2026-10-29","source_published_at":null,"source_url":"https://futurodasaude.com.br/biopsia-liquida-oncologia-brd-einstein/","source_name":"Futuro da Saúde","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":["regulatory_uncertainty","compliance_risk"],"opportunity_flags":["market_entry_opportunity","partnership_opportunity"],"trend_signals":["liquid_biopsy_adoption","precision_oncology_expansion"]},"intelligence":{"intel_id":"9829e1c3-19fd-4ec0-8d56-695439c8685a","version":1,"event_type":"产品上线","event_date":null,"main_entities":[{"name":"Genesis Genomics","role":"Einstein与Grupo Fleury合资成立的基因组医学企业，在巴西推出Galleri检测","type":"company","country":"巴西","normalized_name":null},{"name":"Galleri","role":"可筛查50多种肿瘤的液体活检检测产品","type":"product","country":"巴西","normalized_name":null},{"name":"Einstein","role":"Genesis Genomics合资方之一，精准医学项目参与方","type":"company","country":"巴西","normalized_name":null},{"name":"Grupo Fleury","role":"Genesis Genomics合资方之一","type":"company","country":"巴西","normalized_name":null},{"name":"Fernando Moura","role":"Einstein精准医学项目医疗经理、肿瘤科医生，评论液体活检前景","type":"person","country":"巴西","normalized_name":null},{"name":"Isabella Werneck","role":"巴西病理学会（SBP）病理委员会代表，评论液体活检临床用途","type":"person","country":"巴西","normalized_name":null},{"name":"巴西病理学会（SBP）","role":"巴西病理行业组织，其代表评述液体活检在术后评估等场景的用途","type":"sector","country":"巴西","normalized_name":null}],"main_action":"Genesis Genomics在巴西推出Galleri液体活检检测，可筛查50多种肿瘤。","key_numbers":[{"unit":"种","label":"可筛查肿瘤类型","value":"50多"},{"unit":"岁","label":"适用年龄","value":"50以上"},{"unit":"人","label":"PATHFINDER 2研究参与人数","value":"超过3.5万"},{"unit":"%","label":"阳性结果中早期肿瘤占比","value":"71"},{"unit":"%","label":"预测可能来源准确率","value":"91.3"},{"unit":"%","label":"特异性","value":"99.6"},{"unit":"%","label":"假阳性率","value":"0.4至0.8"},{"unit":"个月","label":"无异常时免费复检窗口","value":"3至6"}],"facts":[{"verified":false,"statement":"Genesis Genomics由Einstein与Grupo Fleury合资成立，并在巴西推出Galleri液体活检检测。","source_excerpt":null},{"verified":false,"statement":"Galleri检测通过普通血液样本进行，可筛查50多种肿瘤，适用于50岁以上无症状人群、有一级亲属癌症家族史者及有吸烟等风险因素人群。","source_excerpt":null},{"verified":false,"statement":"该检测仅作为癌症预防性筛查的补充，不替代乳腺X线摄影和结肠镜检查等官方筛查方案。","source_excerpt":null},{"verified":false,"statement":"若结果呈阳性，需进一步检查确认；若诊断性检查未在所指部位发现异常，可在3至6个月内免费复检一次。","source_excerpt":null},{"verified":false,"statement":"PATHFINDER 2研究于2021年12月至2024年7月在美国和加拿大开展，超过3.5万人参与。","source_excerpt":null},{"verified":false,"statement":"在癌症信号阳性结果中，71%最终诊断为I至III期早期肿瘤，预测可能来源的准确率为91.3%，特异性为99.6%，假阳性率为0.4%至0.8%。","source_excerpt":null}],"assessments":[{"statement":"Galleri在巴西的定位是补充筛查而非确诊工具，短期对官方筛查路径的替代性有限。","confidence":"high","basis_fact_index":null},{"statement":"若本地临床验证和支付路径明确，液体活检有望成为巴西精准肿瘤学的新增长点。","confidence":"medium","basis_fact_index":null},{"statement":"PATHFINDER 2数据表现较强，但单来源报道且未提供巴西本地监管批准细节，落地确定性仍需核验。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"user","priority":"high","description":"核验Galleri在巴西的ANVISA注册或体外诊断监管状态及报销路径。"},{"target":"both","priority":"normal","description":"跟踪Genesis Genomics首批检测结果和PATHFINDER 2同行评议发表情况。"},{"target":"system","priority":"normal","description":"建立巴西液体活检与癌症早筛市场监测清单。"}],"affected_audience":["50岁以上无症状人群","有一级亲属癌症家族史者","有吸烟等风险因素人群","巴西肿瘤高危人群","巴西医疗机构与病理实验室"],"risk_flags":["regulatory_uncertainty","compliance_risk"],"opportunity_flags":["market_entry_opportunity","partnership_opportunity"],"trend_signals":["liquid_biopsy_adoption","precision_oncology_expansion"],"follow_up_needed":true,"follow_up_questions":["Galleri在巴西是否已获ANVISA注册或批准？监管类别是什么？","检测定价、自费或保险覆盖情况以及Genesis Genomics商业化目标如何？","PATHFINDER 2是否已有同行评议论文或巴西本地验证数据？","首批检测结果及阳性后续诊断路径如何管理？"],"related_topics":["液体活检","癌症早筛","Galleri","Genesis Genomics","巴西精准医疗","PATHFINDER 2","循环肿瘤DNA"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-29T11:04:26.410Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/article-20261029-3295a0","api_url":"https://chinabrazilinsight.com/api/public/content/article-20261029-3295a0","markdown_url":"https://chinabrazilinsight.com/api/public/content/article-20261029-3295a0?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/article-20261029-3295a0?view=json","last_updated":"2026-10-29T11:04:26.458Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}